Alnylam Historical Financial Ratios
| ALNY Stock | USD 149.96 6.01 4.18% |
Alnylam Pharmaceuticals is presently reporting on over 111 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, Days Sales Outstanding of 60.78 or Free Cash Flow Yield of 0.0018 will help investors to properly organize and evaluate Alnylam Pharmaceuticals financial condition quickly.
Alnylam |
About Alnylam Financial Ratios Analysis
Alnylam PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Alnylam Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Alnylam financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Alnylam Pharmaceuticals history.
Alnylam Pharmaceuticals Financial Ratios Chart
Alnylam Pharmaceuticals financial ratios usually calculated using numerical values taken directly from Alnylam Pharmaceuticals financial statements such as income statements or balance sheets. They help investors to obtain meaningful information about Alnylam Pharmaceuticals. Most financial ratios help to conduct quantitative analysis to assess vital information about the company's valuation as well as profitability and liquidity indicators such as leverage, growth, profit margins, and different types of rates of return.
At this time, Alnylam Pharmaceuticals' Intangibles To Total Assets are fairly stable compared to the past year. Current Ratio is likely to rise to 5.83 in 2024, whereas Price To Sales Ratio is likely to drop 12.42 in 2024. Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Alnylam Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Alnylam Pharmaceuticals sales, a figure that is much harder to manipulate than other Alnylam Pharmaceuticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company’s stock price to its revenues, calculated by dividing the company’s market cap by its total sales or revenue over a 12-month period.Inventory Turnover
A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.Most ratios from Alnylam Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Alnylam Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.At this time, Alnylam Pharmaceuticals' Intangibles To Total Assets are fairly stable compared to the past year. Current Ratio is likely to rise to 5.83 in 2024, whereas Price To Sales Ratio is likely to drop 12.42 in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 1.91 | 1.72 | 5.59 | 5.87 | Days Of Inventory On Hand | 319.57 | 278.83 | 104.82 | 99.58 |
Alnylam Pharmaceuticals fundamentals Correlations
Click cells to compare fundamentals
Alnylam Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Alnylam Pharmaceuticals fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 57.26 | 30.32 | 23.79 | 27.88 | 13.08 | 12.42 | |
| Ptb Ratio | 8.75 | 14.71 | 34.15 | (182.78) | (108.36) | (102.94) | |
| Days Sales Outstanding | 71.44 | 75.85 | 85.85 | 83.72 | 65.44 | 60.78 | |
| Book Value Per Share | 13.17 | 8.84 | 4.97 | (1.3) | (1.77) | (1.68) | |
| Free Cash Flow Yield | (0.0333) | (0.0459) | (0.0357) | (0.0212) | 0.001754 | 0.001842 | |
| Invested Capital | 0.4 | 0.51 | 1.7 | (8.34) | (11.06) | (10.5) | |
| Operating Cash Flow Per Share | (2.55) | (5.35) | (5.42) | (4.45) | 0.83 | 0.88 | |
| Capex To Depreciation | (2.58) | (0.95) | (0.85) | (0.84) | (1.15) | (1.21) | |
| Pb Ratio | 8.75 | 14.71 | 34.15 | (182.78) | (108.36) | (102.94) | |
| Ev To Sales | 56.16 | 30.37 | 24.0 | 28.31 | 14.1 | 13.39 | |
| Free Cash Flow Per Share | (3.83) | (5.96) | (6.06) | (5.04) | 0.34 | 0.35 | |
| Roic | (0.47) | (0.54) | (0.45) | (0.68) | (0.13) | (0.14) | |
| Inventory Turnover | 0.44 | 0.85 | 1.14 | 1.31 | 3.48 | 3.66 | |
| Net Income Per Share | (8.11) | (7.46) | (7.2) | (9.3) | (3.52) | (3.7) | |
| Days Of Inventory On Hand | 820.65 | 431.64 | 319.57 | 278.83 | 104.82 | 99.58 | |
| Payables Turnover | 0.5 | 1.5 | 1.91 | 1.72 | 5.59 | 5.87 | |
| Sales General And Administrative To Revenue | 5.1 | 2.18 | 1.19 | 0.74 | 0.44 | 0.41 | |
| Research And Ddevelopement To Revenue | 2.98 | 1.33 | 0.94 | 0.85 | 0.55 | 0.52 | |
| Capex To Revenue | (0.64) | (0.14) | (0.0905) | (0.0695) | (0.034) | (0.0357) | |
| Cash Per Share | 14.06 | 16.3 | 20.56 | 18.02 | 19.53 | 10.34 | |
| Pocfratio | (45.2) | (24.3) | (31.3) | (53.43) | 229.54 | 241.02 | |
| Capex To Operating Cash Flow | 0.5 | 0.11 | 0.12 | 0.13 | (0.6) | (0.57) | |
| Pfcf Ratio | (30.06) | (21.81) | (27.97) | (47.15) | 569.99 | 598.49 | |
| Days Payables Outstanding | 726.5 | 243.01 | 191.24 | 212.09 | 65.28 | 62.02 | |
| Roe | (0.62) | (0.84) | (1.45) | 7.15 | 2.0 | 2.1 | |
| Ev To Operating Cash Flow | (44.32) | (24.34) | (31.58) | (54.27) | 247.5 | 259.87 | |
| Pe Ratio | (14.2) | (17.41) | (23.55) | (25.57) | (54.31) | (51.59) | |
| Ev To Free Cash Flow | (29.48) | (21.84) | (28.22) | (47.89) | 614.57 | 645.3 | |
| Earnings Yield | (0.0704) | (0.0574) | (0.0425) | (0.0391) | (0.0184) | (0.0193) | |
| Net Debt To E B I T D A | 0.26 | (0.0319) | (0.25) | (0.51) | (8.2) | (7.79) | |
| Current Ratio | 1.81 | 1.91 | 2.41 | 3.51 | 3.08 | 5.83 | |
| Tangible Book Value Per Share | 13.17 | 8.84 | 4.97 | (3.47) | (7.35) | (6.99) | |
| Receivables Turnover | 5.11 | 4.81 | 4.25 | 4.36 | 5.58 | 5.3 | |
| Graham Number | 49.02 | 38.53 | 28.36 | 16.49 | 11.84 | 11.24 | |
| Shareholders Equity Per Share | 13.17 | 8.84 | 4.97 | (1.3) | (1.77) | (1.68) |
Alnylam Pharmaceuticals Investors Sentiment
The influence of Alnylam Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Alnylam. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Alnylam Pharmaceuticals' public news can be used to forecast risks associated with an investment in Alnylam. The trend in average sentiment can be used to explain how an investor holding Alnylam can time the market purely based on public headlines and social activities around Alnylam Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Alnylam Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Alnylam Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Alnylam Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Alnylam Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Alnylam Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Alnylam Pharmaceuticals' short interest history, or implied volatility extrapolated from Alnylam Pharmaceuticals options trading.
Pair Trading with Alnylam Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alnylam Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alnylam Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Alnylam Stock
| 0.62 | EWTX | Edgewise Therapeutics Financial Report 9th of May 2024 | PairCorr |
Moving against Alnylam Stock
| 0.79 | OGN | Organon | PairCorr |
| 0.72 | VKTX | Viking Therapeutics | PairCorr |
| 0.69 | KRYS | Krystal Biotech Earnings Call This Week | PairCorr |
| 0.67 | HCWB | HCW Biologics | PairCorr |
| 0.65 | LLY | Eli Lilly Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Alnylam Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alnylam Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alnylam Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alnylam Pharmaceuticals to buy it.
The correlation of Alnylam Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alnylam Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alnylam Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alnylam Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Complementary Tools for Alnylam Stock analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |
Is Alnylam Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alnylam Pharmaceuticals. If investors know Alnylam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alnylam Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.52) | Revenue Per Share 14.637 | Quarterly Revenue Growth 0.312 | Return On Assets (0.05) | Return On Equity (15.01) |
The market value of Alnylam Pharmaceuticals is measured differently than its book value, which is the value of Alnylam that is recorded on the company's balance sheet. Investors also form their own opinion of Alnylam Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Alnylam Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alnylam Pharmaceuticals' market value can be influenced by many factors that don't directly affect Alnylam Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alnylam Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alnylam Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alnylam Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.